HC Wainwright Weighs in on Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings of ($0.04) per share for the quarter, down from […]

Related Keywords

,Capital Management ,Oramed Pharmaceuticals ,News Ratings For Oramed Pharmaceuticals Daily ,Murchinson Ltd ,Oramed Pharmaceuticals Company Profile ,Oramed Pharmaceuticals Stock ,Virtu Financial ,Nasdaq ,Rathbones Group ,Hedge Funds Weigh In On Oramed Pharmaceuticals ,Oramed Pharmaceuticals Inc ,Free Report ,Oramed Pharmaceutical ,Get Free Report ,Pharmaceuticals Inc ,Oramed Pharmaceuticals Daily ,